Physician profile
Anit Dua
NPI 1134119712
$2,059.55
in general payments reported to CMS, 2019-2025
28 companies · $295 in 2025
The $295 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $281 · 2021: $273 · 2022: $214 · 2023: $366 · 2024: $246 · 2025: $295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $906.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $906.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $494.27 | 2019-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $292.60 | 2019-2023 | Xifaxan |
| Merck Sharp & Dohme LLC | $233.35 | 2021-2025 | Verquvo, Steglatro |
| Astrazeneca Pharmaceuticals Lp | $169.03 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $149.67 | 2020-2025 | Jardiance, Mounjaro, Zepbound |
| Novartis Pharmaceuticals Corporation | $97.25 | 2019-2025 | |
| Novo Nordisk INC | $76.82 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $61.68 | 2024-2025 | |
| Abbott Laboratories | $48.88 | 2024-2025 | Freestyle Libre 3 |
| Abbvie INC. | $37.47 | 2023 | Vraylar |
| Mylan Specialty L.P. | $34.99 | 2021 | |
| Intra-Sana Laboratories | $32.95 | 2023 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Allergan, INC. | $30.79 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $29.48 | 2023-2025 | Dupixent, Evkeeza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.41 | 2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mannkind Corporation | $24.62 | 2019 | |
| Lucid Diagnostics INC. | $24.04 | 2024 | |
| Corium, LLC | $21.45 | 2023 | Adlarity |
| Amarin Pharma, INC. | $21.22 | 2020 | |
| Daiichi Sankyo INC. | $19.24 | 2024 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $18.99 | 2025 | Caplyta |
| Genentech USA, INC. | $18.19 | 2023 | Xolair |
| Astellas Pharma US INC | $17.60 | 2019 | |
| Irhythm Technologies, INC. | $17.33 | 2022 | |
| Sanofi Pasteur INC. | $17.08 | 2025 | |
| Medtronic, INC. | $17.02 | 2023 | Intellis Adaptivestim |
| Dexcom, INC. | $15.02 | 2025 | Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anit Dua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.